Clinical Study
Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
Table 2
Visual and anatomical outcomes after aflibercept conversion.
| Outcomes | Baseline | 3 months | 6 months | | P valuea | | P valuea |
| BCVA (number of ETDRS letters) | 42.5 ± 12.5 | 42.3 ± 10.5 | >0.05b | 42.8 ± 10.0 | >0.05b | BCVA (logMAR) | 0.24 | 0.26 | | 0.24 | | 1-mm CSF (microns) | 449 ± 179 | 224 ± 131 | <0.001b | 269 ± 145 | <0.001b | Maximum height of PED (microns) | 262 ± 134 | 181 ± 118 | <0.001b | 183 ± 100 | <0.001b | Subfoveal choroidal thickness (microns) | 192 ± 67 | 159 ± 58 | <0.01b | 167 ± 51 | <0.01b | Presence of intraretinal fluid, number (%) | 27 (87) | 8 (26) | <0.0001c | 12 (39) | <0.0001c | Presence of subretinal fluid, number (%) | 19 (61) | 8 (26) | <0.001c | 8 (26) | <0.001c | Presence of PED, number (%) | 31 (100) | 23 (74) | <0.01c | 27 (87) | >0.05c | Number of aflibercept injections | | | | 4.5 ± 1.3 | |
|
|
Values are mean ± SD unless otherwise indicated. BCVA: best-corrected visual acuity; ETDRS: early treatment diabetic retinopathy study; logMAR: logarithm of the minimal angle of resolution; CSF: central subfield retinal thickness; PED: pigment epithelial detachment.
aCompared with baseline.
bPaired -test.
cMcNemar’s test.
|